Skip to main content
Top navigation
  • Sustainability reports
  • Focus area: Increase resource efficiency
  • Governance
  • Please fill out this field

Main navigation

    • Our offering
        • Solids & others
            • Manufacturing
                • Solids
                • Semi-solids
                • Liquids
                • Pharmaceutical packaging
                • Controlled drugs
                • High Potent
        • Sterile delivery
            • Manufacturing
                • Sterile vial filling
                • PFS and cartridges
                • Lyophilisation
                • Blow-fill-seal
                • Ampoules
            • Specialised services
                • Ophthalmics
                • Beta-lactams
                • Vaccine manufacturing
        • Advanced Bio
            • Modalities & services
                • xRNA therapies
                • Virus & viral vectros
                • Microbial & live biotherapeutic products
                • Recombinant proteins
            • Continuous manufacturing
            • Innovations & collaborations
        • Additional services
            • ReciPredict
            • Analytical services
            • Regulatory
            • New product introduction
                • Technology Transfer
                • Product development
    • Resources
    • About us
        • About us
            • Our leadership
            • Why partner with us
            • Locations
        • Sustainability
            • Sustainability reports
            • Sustainability strategy
            • Net Zero commitment
            • Governance
        • News & Events
            • Press releases
            • Events
    • Careers
        • Careers
            • Who we are
            • Working with us
            • What you can do
            • Job search
    • Contact
Linkedin
Contact
Please fill out this field
No banner Image

Press releases

  • Home
  • About us
  • Press releases
  • Facebook
  • Linkedin
  • Twitter
  • Email

BU-NOT-SET

CONTACT US
September 08 2025
Recipharm partners with NeuroSense Therapeutics to advance ALS therapy PrimeC toward Phase 3 trials
September 02 2025
Recipharm strengthens brand to reinforce customer focus and manufacturing leadership
June 23 2025
Recipharm strengthens BFS leadership with new development contracts, enabling over 90% API savings
June 18 2025
ReciBioPharm celebrates strong first half of 2025 with momentum for the future
June 17 2025
ReciBioPharm unveils ground-breaking, real-time PAT platform at Bio Summit
June 09 2025
University of Oxford and ReciBioPharm expand strategic collaboration in fight against malaria
May 13 2025
Recipharm and PLG announce strategic partnership to accelerate development projects
May 08 2025
NewBiologix licenses Xcell-Eng-HEK293 cell line to ReciBioPharm for development and manufacture of Adeno-Associated Virus (AAV) therapeutics
April 09 2025
Recipharm exceeds sustainability goals with major milestones
March 14 2025
Recipharm reports record 2024 revenue and strategic milestones

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • …
  • Next page
  • Last page

Footer Webfrom

contact form

Let’s discuss your 
next project

Share your details and start your journey with our global CDMO team.

Stay updated
https://se.linkedin.com/company/recipharm https://www.youtube.com/channel/UCr-bw7pCCkYZfeImOwTfNRg
Footer
  • Privacy policy
  • Cookies
  • Website terms
  • Sitemap
  • Cookie settings
  • Terms & conditions
  • Code of Conduct
© 2025

Recipharm AB. All rights reserved. RECIPHARM® is a registered trademark owned by Recipharm AB.

Delivered by Investisdigital [iDX]